Catalyst Pharmaceuticals (CPRX) Income towards Parent Company (2010 - 2026)

Catalyst Pharmaceuticals has reported Income towards Parent Company for 17 years, with the latest figure at $63.7 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 12.33% year-over-year to $63.7 million; the trailing twelve-month figure through Mar 2026 stood at $214.6 million (up 14.19% YoY), and the FY2025 full-year result was $207.6 million, up 34.4% from the prior year.
• Income towards Parent Company for Q1 2026 stood at $63.7 million, up from $45.9 million in the prior quarter.
• The five-year high for Income towards Parent Company was $63.7 million in Q1 2026, with the low at -$30.8 million in Q3 2023.
• Historically, Income towards Parent Company has averaged $33.6 million across 5 years, with a median of $37.8 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company surged 267.96% — and 2023, when it plunged 235.24%.
• Catalyst Pharmaceuticals' Income towards Parent Company stood at $34.3 million in 2022, then slumped by 50.26% to $17.0 million in 2023, then jumped by 172.8% to $46.5 million in 2024, then fell by 1.18% to $45.9 million in 2025, then soared by 38.75% to $63.7 million in 2026.
• The last three Income towards Parent Company figures came in at $63.7 million (Q1 2026), $45.9 million (Q4 2025), and $52.8 million (Q3 2025), per Business Quant data.